Comparative Single-Dose Pharmacokinetics of Clonazepam following Intravenous, Intramuscular and Oral Administration to Healthy Volunteers
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The objective was to assess the single-dose pharmacokinetics of clonazepam following i.m., p.o. and i.v. administration. In an open-label, three-way crossover study, 12 healthy volunteers were randomized to receive a single dose of 2 mg clonazepam either by the i.m., p.o. or i.v. route. Serial blood samples were collected up to 120 h after drug administration. Plasma concentrations of clonazepam were determined by electron-capture gas-liquid chromatography. The absorption rates of clonazepam after i.m. and p.o. administration of clonazepam were significantly different from each other, as reflected by the respective mean values of maximum plasma concentration (C max 11.0 vs. 14.9 ng·ml–1) and time to reach maximum concentration (t max 3.1 vs. 1.7 h). Secondary plasma peaks of clonazepam were observed in 9 volunteers after i.m. injection (C max 9.9 ng·ml–1; t max 10.4 h). A comparison of the area under the plasma concentration-time curves (AUC) shows that the i.m. route is equivalent to the oral route (AUC 0–∞ 620 vs. 561 ng·h·ml–1). Clonazepam was almost completely absorbed after i.m. and p.o. administration, as shown by the mean absolute bioavailability of 93 and 90%, respectively. No significant differences existed between the elimination half-lives (i.v. 38.0 h; i.m. 43.6 h; p.o. 39.0 h). The average clearance and volume of distribution (V Z) were 55 ml·min–1 and 180 liters, respectively. In conclusion, the observed differences in C max and t max after i.m. and p.o. administration were consistent with a slower absorption rate of clonazepam after i.m. injection. The systemic exposure to clonazepam was not affected by the route of extravascular administration. Statistical evaluation of these kinetic data showed differences in the absorption rate, so that clonazepam given by the i.m. route is not bioequivalent to the oral route. On the basis of the results of this study, we would recommend the same i.m. and p.o. dose in epileptic patients, but therapeutic response would be expected to be less predictable and to occur later in the case of i.m. administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schuirmann, D. J. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01068419 · Cited by 2,696
Cited by
Zuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J. E. C., Guimarães, F. S., & Crippa, J. A. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00259 · Cited by 294
Pharmacological Management of Acute Agitation
Battaglia, J. (2005) · Drugs · doi:10.2165/00003495-200565090-00003 · Cited by 254
Kienitz, R., Kay, L., Beuchat, I., Gelhard, S., von Brauchitsch, S., Mann, C., Lucaciu, A., Schäfer, J.-H., Siebenbrodt, K., Zöllner, J.-P., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00940-2 · Cited by 139
“[151], oral droplets [152] or subcutaneous [153] formulations.”
BackgroundKadono, K., Akabane, T., Tabata, K., Gato, K., Terashita, S., & Teramura, T. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029322 · Cited by 52
Moylan, S., Staples, J., Ward, S. A., Rogerson, J., Stein, D. J., & Berk, M. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822d0012 · Cited by 34
“A few studies have demonstrated successful discontinuation of clonazepam,(54,60) with decreased withdrawal symptoms attributed to its prolonged elimination half-life.(58) As previously mentioned, alprazolam prescription rates are increasing despite no longer being a recommended firstline treatment strategy for PD.”
Background
Metadata
- Authors
- Crevoisier, C., Delisle, M. C., Joseph, I., & Foletti, G.
- Venue
- European Neurology
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 49
- Issue
- 3
- Pages
- 173-177
- ISSN
- 0014-3022 (ISSN-L)
- 1421-9913
- OpenAlex
- W2008227560
- Cited by
- 62
- References
- 1
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.